FDA Approves First Treatment for Rare Neurological Disorder, Alexander Disease

The U.S. FDA has approved Zanvastro (zilganersen) as the first treatment for Alexander disease, a rare and progressive neurological disorder. This approval provides a new therapeutic option for both pediatric and adult patients, directly addressing the abnormal protein accumulation characteristic of the condition.